Recent Cap Raising It also enabled us to increase Institutional shareholdings to approximately one third of the share register, up from only 5% six months ago. We are pleased that new institutional investors came from four different countries, which is a positive step in the evolution of our share register.
1) t is very frustrating for all stakeholders, not least the patients and their families, that the unprecedented COVID-19 pandemic arrived during this highly anticipated trial, causing travel restrictions and safety risks. After ending a 3 month pause in enrolment in June 2020, I am confident that ACADIA is taking all appropriate measures, working with each trial site individually to get the best outcome. I also remain confident about the potential impact of trofinetide on this devastating condition, having experienced the two clinical trials that Neuren conducted in girls and women with Rett syndrome. 2) we have started discussions with national regulatory authorities in Europe. 3) NNZ2591- the Phase 1 trial to characterize safety and PK in healthy volunteers is continuing in Western Australia, and we are evaluating alternative designs for the Phase 2 trials. We will provide updates on all of these in due course. 4) will conclude by noting that there are very few companies on the ASX with an ongoing single Phase 3 trial fully funded by a partner and four other programs either in or soon to start Phase 2. All five are serious conditions in children with no approved medicines.
NEU Price at posting:
$1.26 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)